TOP TIERMARKET NEWSWIRE

News & sentiment

ROCHE HLDG LTD ADR (RHHBY) — News & AI sentiment

ROCHE HLDG LTD ADR (RHHBY) news roundup. 4 stories in the past week, 14 over 30 days. Average 30-day sentiment is 60.4/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

4

avg sentiment 59.3/100

30d stories

14

avg sentiment 60.4/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

RHHBY news in the last 24 hours, 7 days, 30 days and 90 days

How much RHHBY coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	RHHBY stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	4	59.3/100	RHHBY headlines →
Last 30 days	14	60.4/100	RHHBY headlines →
Last 90 days	46	61.1/100	RHHBY headlines →

Latest stories on RHHBY

RBC Capital initiates Roche stock with outperform rating on pipeline potential

Investing.com Analyst Ratings61 · neutralanalyst

4d ago

Roche initiated with an Outperform at RBC Capital

The Fly61 · neutralanalyst

5d ago

Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

GlobeNewswire58 · neutralgeneral

6d ago

Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline

GlobeNewswire57 · neutralgeneral

6d ago

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

GlobeNewswire50 · neutralgeneral

Sep 2

Roche announces new two-year data from Phase IIIb/IV SALWEEN study

The Fly50 · neutralgeneral

Aug 28

Roche gains expanded use of diagnostic tests to identify eligible Ziihera patients

Seeking Alpha63 · neutralproduct/pr

Aug 26

Roche receives FDA approval for companion diagnostic tests for Ziihera

The Fly73 · bullishproduct/pr

Aug 26

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

StockTitan73 · bullishproduct/pr

Aug 26

Can This Stock, Just Above A Buy Zone, Take On Roche?

Investors.com58 · neutralanalyst

Aug 25

Roche’s Alzheimer’s blood test wins FDA clearance

Seeking Alpha73 · bullishproduct/pr

Aug 24

Why is Roche AG Participation stock sliding today?

Investing.com Markets42 · neutralgeneral

Aug 24

Roche’s Genentech unit to build $750M fill-finish facility in Ohio

Seeking Alpha63 · neutralproduct/pr

Aug 20

Roche’s Genentech announces $750M manufacturing expansion in Hillsboro, GA

The Fly63 · neutralgeneral

Aug 20

Roche Is Getting More Benefit Of The Doubt On Improving Execution

Seeking Alpha58 · neutralgeneral

Aug 13

Roche upgraded at Morgan Stanley on growth, pipeline upside

Seeking Alpha61 · neutralanalyst

Aug 7

Roche announces partnership with Ivy Tech to help strengthen Indiana's medical laboratory workforce

PR Newswire58 · neutralproduct/pr

Jul 30

Market Update: NLY, BRO, SANM, SLB, RHHBY, BKR

Yahoo Top50 · neutralgeneral

Jul 28

Bernstein raises Roche stock price target on R&D outlook to CHF434.50

Investing.com Analyst Ratings61 · neutralanalyst

Jul 27

Roche launches FDA-cleared PCR test; expands women's health portfolio

Seeking Alpha63 · neutralproduct/pr

Jul 24

Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

StockTitan67 · bullishproduct/pr

Jul 24

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

StockTitan73 · bullishproduct/pr

Jul 24

Roche jumps despite reiterated 2026 outlook

Seeking Alpha58 · neutralgeneral

Jul 23

Roche Holding AG 2026 Q2 - Results - Earnings Call Presentation

Seeking Alpha50 · neutralearnings

Jul 23

Why is Roche stock climbing today?

Investing.com Markets50 · neutralgeneral

Jul 23

Open RHHBY in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →